Dynavax Technologies Corporation  

(Public, NASDAQ:DVAX)   Watch this stock  
Find more results for DVAX
4.35
+0.05 (1.16%)
After Hours: 4.35 0.00 (0.00%)
Jan 18, 4:48PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.25 - 4.38
52 week 3.20 - 27.92
Open 4.35
Vol / Avg. 563,345.00/1.44M
Mkt cap 165.67M
P/E     -
Div/yield     -
EPS -2.87
Shares 38.53M
Beta 1.93
Inst. own 84%
Mar 6, 2017
Q4 2016 Dynavax Technologies Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 9, 2016
Dynavax Technologies Corp Cancer R&D Day
Nov 14, 2016
Dynavax Technologies Corp Conference Call Regarding Biologics License Application (BLA) for HEPLISAV-BT - Webcast
Nov 7, 2016
Q3 2016 Dynavax Technologies Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -21416.05% -2636.89%
Operating margin -21504.94% -2635.65%
EBITD margin - -2517.33%
Return on average assets -90.68% -60.18%
Return on average equity -112.66% -74.28%
Employees 234 -
CDP Score - -

Address

2929 7th St Ste 100
BERKELEY, CA 94710-2753
United States - Map
+1-510-8485100 (Phone)
+1-510-8481327 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company's lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. Its SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. Its advanced inflammatory disease candidate is AZD1419. Its pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

Officers and directors

Arnold L. Oronsky Ph.D. Independent Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Eddie Gray Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Michael S. Ostrach Principal Financial Officer, Vice President, General Counsel, Chief Business Officer
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert L. Coffman Ph.D. Senior Vice President, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
David F. Novack Senior Vice President - Operations and Quality
Age: 53
Bio & Compensation  - Reuters
David Louis Johnson Chief Accounting Officer, Vice President
Age: 57
Bio & Compensation  - Reuters
Robert Janssen M.D. Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs
Age: 61
Bio & Compensation  - Reuters
Laura A. Brege Director
Age: 58
Bio & Compensation  - Reuters
Natale S. Ricciardi Director
Age: 67
Bio & Compensation  - Reuters
Francis R Cano Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters